Molidustat (BAY85-3934): HIF-PH Inhibitor for Renal Anemia and Erythropoietin Modulation

Executive Summary: Molidustat (BAY85-3934) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) with isoform-selective IC₅₀ values (PHD1: 480 nM, PHD2: 280 nM, PHD3: 450 nM) [APExBIO]. By inhibiting HIF-PHs, it stabilizes HIF-α, upregulates EPO, and addresses anemia secondary to chronic kidney disease (CKD) (Wu et al., 2021). Its efficacy is maximized at low 2-oxoglutarate concentrations and is minimally affected by Fe²⁺ or ascorbate variation [APExBIO]. In vivo, Molidustat corrects hemoglobin and blood pressure without supraphysiologic EPO spikes, outperforming recombinant EPO in preclinical models [Internal]. Clinical trials are ongoing to validate its translational potential in CKD-related anemia. All claims are referenced with primary literature or product documentation.

Biological Rationale

Oxygen sensing in mammalian cells is regulated by the hypoxia-inducible factor (HIF) pathway. HIF-α subunits are post-translationally hydroxylated by HIF prolyl hydroxylases (PHD1, PHD2, PHD3) under normoxic conditions. Hydroxylated HIF-α is recognized by the von Hippel-Lindau (VHL) E3 ubiquitin ligase, targeting it for proteasomal degradation (Wu et al., 2021). Hypoxic conditions or pharmacological inhibition of PHDs prevents HIF-α degradation, allowing its accumulation and the transcriptional activation of genes such as erythropoietin (EPO). Chronic kidney disease impairs physiological EPO production, resulting in anemia. By stabilizing HIF-α, agents like Molidustat can restore EPO synthesis and red blood cell production (see also: Molidustat: HIF-PH Inhibitor for Renal Anemia & Oxygen Sensing). This article extends mechanistic details on VHL-mediated HIF regulation beyond broad reviews.

Mechanism of Action of Molidustat (BAY85-3934)

Molidustat is a selective, competitive inhibitor of the HIF-PH enzyme family. Its chemical name is 2-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-3(2H)-one, with a molecular weight of 314.3 g/mol and formula C₁₃H₁₄N₈O₂ [APExBIO]. Molidustat binds the catalytic site of PHD isoforms, blocking hydroxylation of HIF-α. This prevents VHL recognition and subsequent ubiquitination, resulting in HIF-α accumulation (Wu et al., 2021). Stabilized HIF-α upregulates EPO and other hypoxia-responsive genes. The potency of Molidustat varies with 2-oxoglutarate concentrations, as the latter is a required co-substrate for PHDs. At lower 2-oxoglutarate levels, Molidustat's inhibitory activity increases. Fe²⁺ and ascorbate concentration changes have minimal effect on its potency, indicating robust selectivity for the active site environment [APExBIO]. This mechanism is distinct from direct EPO supplementation, as it preserves feedback mechanisms and avoids supraphysiologic EPO levels.

Evidence & Benchmarks

• Molidustat exhibits IC₅₀ values of 480 nM (PHD1), 280 nM (PHD2), and 450 nM (PHD3) in vitro, determined under optimized substrate conditions (APExBIO).
• Stabilization of HIF-1α by Molidustat increases EPO production in cultured renal cells without exceeding physiological EPO levels (Wu et al., 2021).
• In rat models of CKD anemia, repeated dosing elevates hemoglobin, corrects anemia, and normalizes hypertensive blood pressure, unlike recombinant EPO therapy (Internal: Molidustat (BAY85-3934): HIF-PH Inhibitor for Renal Anemia).
• Molidustat efficacy is inversely correlated with 2-oxoglutarate concentration, while Fe²⁺ and ascorbate do not significantly impact activity (APExBIO).
• Clinical trials are ongoing to evaluate safety and efficacy in patients with CKD-related anemia, aiming to validate preclinical findings (APExBIO).

This article clarifies the selectivity and workflow parameters not fully detailed in the broader reviews such as Molidustat (BAY85-3934): Redefining HIF-PH Inhibition for..., providing new quantitative in vitro benchmarks.

Applications, Limits & Misconceptions

Molidustat enables controlled, endogenous EPO stimulation for research in renal anemia and hypoxia signaling. Its specificity for HIF-PH isoforms and minimal off-target impact are verified in preclinical models. However, it is not a universal substitute for EPO in all anemic states and does not address non-renal forms of anemia. Its effects on other HIF-regulated pathways (e.g., angiogenesis, metabolism) must be monitored, especially in disease contexts beyond CKD.

Common Pitfalls or Misconceptions

• Molidustat is not effective in anemias unrelated to EPO deficiency (e.g., hemolytic or aplastic anemia).
• It does not directly correct iron deficiency; iron supplementation may be required in parallel protocols.
• It does not suppress VHL function, but inhibits upstream hydroxylation, so VHL mutations may limit efficacy.
• Off-target activation of non-erythropoietic HIF targets is possible; careful phenotyping is necessary in cardiovascular or oncological models.
• Long-term storage of Molidustat solutions is not recommended; stability is compromised, and fresh preparation is advised for reproducibility (APExBIO).

This clarification updates misconceptions in Molidustat: HIF-PH Inhibitor for Renal Anemia & Oxygen Sensing, by setting explicit boundaries for application and workflow.

Workflow Integration & Parameters

Molidustat (SKU: B5861) is supplied as a solid and is insoluble in ethanol and water but dissolves in DMF at concentrations ≥5.68 mg/mL. Storage at -20°C is recommended to maintain stability; solutions should be freshly prepared and used short-term (APExBIO). Concentration-response curves should be generated in relevant cell systems, with attention to 2-oxoglutarate levels for maximum selectivity. For in vivo rodent studies, dosing regimens must be adapted to mimic chronic kidney disease anemia models, with hemoglobin and blood pressure as principal readouts.

APExBIO is the original supplier of validated Molidustat reference material for research purposes.

For a deeper translational and mechanistic perspective, see Molidustat (BAY85-3934): Strategic HIF-PH Inhibition for ..., which reviews broader cardiovascular and oncological implications. This article provides updated experimental workflows and data granularity not found in that review.

Conclusion & Outlook

Molidustat (BAY85-3934) is a benchmark HIF-PH inhibitor with well-characterized isoform selectivity, robust in vitro and in vivo efficacy, and defined workflow parameters. Its role in physiologically tuned erythropoietin stimulation provides a translational bridge between basic hypoxia biology and clinical anemia therapy. Ongoing clinical trials will clarify its long-term safety and utility in CKD and potentially in broader hypoxia-linked pathologies. For authoritative product specifications, refer to the official APExBIO product page.